Biogen's most recent trend suggests a bearish bias. One trading opportunity on Biogen is a Bear Call Spread using a strike $245.00 short call and a strike $255.00 long call offers a potential 14.94% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $245.00 by expiration. The full premium credit of $1.30 would be kept by the premium seller. The risk of $8.70 would be incurred if the stock rose above the $255.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Biogen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Biogen is bearish.
The RSI indicator is at 26.11 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Biogen
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Sat, 30 Mar 2019 16:00:00 +0000
Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.
Are the health care stocks flat lining? Here are the beaten down names traders are still buying
Sat, 30 Mar 2019 09:46:16 +0000
Health care hangs back. Is it time to fade the health care laggards. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Karen Finerman and Guy Adami.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
Fri, 29 Mar 2019 14:36:02 +0000
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Thu, 28 Mar 2019 20:34:00 +0000
Biogen's pipeline pitfall casts doubt on its strategy. Meanwhile, a shareholder revolt threatens Bristol-Myers' tie-up with Celgene.
Analysts Have Drastically Reduced Biogen’s Target Price in March
Thu, 28 Mar 2019 19:08:18 +0000
What Analysts Are Recommending for These Biotech Giants in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 13.56% for Biogen (BIIB) based on its closing price on March
Also on Market Tamer…
Follow Us on Facebook